May 2nd 2024
During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Combination Therapies Approaching the Advanced RCC Treatment Paradigm
March 15th 2018Newer combination regimens are about to make their way into the treatment paradigm in RCC, with promising data fueling excitement for these approaching regimens. Each of the combinations approaching addition to the treatment paradigm for patients with RCC incorporates immunotherapy, demonstrating the growing role of this modality.
Read More
Eisai And Merck Collaboration Initiated for the Advancement of Lenvatinib Mesylate
March 9th 2018Lenvatinib mesylate, an oral tyrosine kinase inhibitor, will continue to be developed and commercialized worldwide by its creator, Japan’s Eisai Co. Ltd, in a strategic collaboration with Merck, which is better known as MSD outside of the United States and Canada. The partnership between the 2 companies was announced on March 7.
Read More
Sunitinib Not Granted European Panel Support for Approval in High-Risk RCC
March 7th 2018Based on data from the phase III S-TRAC trial,<span style="font-size:10.8333px"> </span>the European Medicines Agency’s Committee for Medicinal Products for Human Use recently recommended against approving sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.
Read More
Figlin Explains the Many Factors that Dictate Second-Line Treatment Options in mRCC
March 5th 2018Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, professor of medicine, and director, Division of Hematology/Oncology, Cedars-Sinai Medical Center, recently discussed the cases of 2 patients with metastatic renal cell carcinoma.
Read More
Published Data Supports Lenvatinib as Potential New HCC Treatment Option as FDA Weighs Approval
February 27th 2018According to findings from the phase III REFLECT trial now published online in the <em>Lancet,</em><sup> </sup>lenvatinib improved progression-free survival and was noninferior for overall survival compared with sorafenib for the frontline treatment of patients with unresectable hepatocellular carcinoma.
Read More
A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma
February 26th 2018Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC). <br />
Watch